Cancer Research and Treatment

Patient’s Factors at Entering Hospice Affecting Length of Survival in a Hospice Center: Guk Jin Lee, Hye Shin Ahn, Se Eun Go, Ji Hyun Kim, Min Wu Seo, Seung Hun Kang, Yeo Ree Yang, Mi Yeong Lee, Ku Ock Lee, Sang Hoon Chun, Jong Youl Jin; Cancer Res Treat. 2015;47(1):1-8. Published online August 28, 2014; DOI: https://doi.org/10.4143/crt.2013.148

Purpose
In order to provide effective hospice care, adequate length of survival (LOS) in hospice is necessary. However the reported average LOS is much shorter. Analysis of LOS in hospice has not been reported from Korea. We evaluated the duration of LOS and the factors associated with LOS at our hospice center.
Materials and Methods
We retrospectively examined 446 patients who were admitted to our hospice unit between January 2010 and December 2012. We performed univariate and multivariate analysis for analysis of factors associated with LOS.
Results
The median LOS was 9.5 days (range, 1 to 186 days). The LOS of 389 patients (86.8%) was< 1 month. At the time of admission to hospice, 112 patients (25.2%) were completely bedridden, 110 patients (24.8%) had mouth care only without intake, and 134 patients (30.1%) had decreased consciousness, from confusion to coma. The median time interval between the day of the last anticancer treatment and the day of hospice admission was 75 days. By analysis of the results of multivariate analysis, decreased intake and laboratory results showing increased total white blood cell (WBC), decreased platelet count, increased serum creatinine, increased aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) level were poor prognostic factors for survival in hospice.
Conclusion
Before hospice admission, careful evaluation of the patient’s performance, particularly the oral intake, and total WBC, platelet, creatinine, AST, ALT, and LDH level is essential, because these were strong predictors of shorter LOS. In the future, conduct of prospective controlled studies is warranted in order to confirm the relationship between potential prognostic factors and LOS in hospice.

Citations

Citations to this article as recorded by

Changes in the palliative performance scale may be as important as the initial palliative performance scale for predicting survival in terminal cancer patients
Guk Jin Lee, Ji Hyun Gwak, Myoung Sim Kim, Mi Yeong Lee, Seo Ree Kim, Sang Hoon Chun, Jong Youl Jin
Palliative and Supportive Care.2021; 19(5): 547. CrossRef
Safety, Efficacy, and Patient Satisfaction with Initial Peripherally Inserted Central Catheters Compared with Usual Intravenous Access in Terminally Ill Cancer Patients: A Randomized Phase II Study
Eun Ju Park, Kwonoh Park, Jae-Joon Kim, Sang-Bo Oh, Ki Sun Jung, So Yeon Oh, Yun Jeong Hong, Jin Hyeok Kim, Joo Yeon Jang, Ung-Bae Jeon
Cancer Research and Treatment.2021; 53(3): 881. CrossRef
Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study
Min-Seok Seo, In Cheol Hwang, Jaehun Jung, Hwanhee Lee, Jae Hee Choi, Jae-Yong Shim
BMC Palliative Care.2020;[Epub] CrossRef
The Impact of Combined Use of Opioids, Antipsychotics, and Anxiolytics on Survival in the Hospice Setting
Marin Golčić, Renata Dobrila-Dintinjana, Goran Golčić, Aleksandar Čubranić
Journal of Pain and Symptom Management.2018; 55(1): 22. CrossRef
Cancer-related hypercalcemia in oral cancer
T.-C. Lin, K.-L. Liang, L.-C. Lee, C.-Y. Hsu, T.-T. Yen
International Journal of Oral and Maxillofacial Surgery.2018; 47(6): 685. CrossRef
Physical Exercise: An Evaluation of a New Clinical Biomarker of Survival in Hospice Patients
Marin Golčić, Renata Dobrila-Dintinjana, Goran Golčić, Lidija Gović-Golčić, Aleksandar Čubranić
American Journal of Hospice and Palliative Medicine®.2018; 35(11): 1377. CrossRef
Effects of a new medical insurance payment system for hospice patients in palliative care programs in Korea
Youngin Lee, Seung Hun Lee, Yun Jin Kim, Sang Yeoup Lee, Jeong Gyu Lee, Dong Wook Jeong, Yu Hyeon Yi, Young Jin Tak, Hye Rim Hwang, Mieun Gwon
BMC Palliative Care.2018;[Epub] CrossRef
Prediction of Patient Discharge Status Based on Indicators on Admission
Sung-In Chung, Seung Hun Lee, Yun-Jin Kim, Sang-Yeoup Lee, Jeong-Gyu Lee, Yu-Hyeon Yi, Young-Hye Cho, Young-Jin Tak, Hye-Rim Hwang, Eun-Ju Park, Kyung-Mi Kim
The Korean Journal of Hospice and Palliative Care.2018; 21(3): 75. CrossRef
Amyotrophic Lateral Sclerosis Survival Score (ALS-SS): A simple scoring system for early prediction of patient survival
Christian Lunetta, Andrea Lizio, Mario Giovanni Melazzini, Eleonora Maestri, Valeria A. Sansone
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.2016; 17(1-2): 93. CrossRef
Safety, efficacy, and patient-perceived satisfaction of peripherally inserted central catheters in terminally ill cancer patients: a prospective multicenter observational study
Kwonoh Park, Hyun Jung Jun, So Yeon Oh
Supportive Care in Cancer.2016; 24(12): 4987. CrossRef

12,465 View
79 Download
9 Web of Science
10 Crossref

Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer: Kyung Hee Lee, Myung Soo Hyun, Hoon-Kyo Kim, Hyung Min Jin, Jinmo Yang, Hong Suk Song, Young Rok Do, Hun Mo Ryoo, Joo Seop Chung, Dae Young Zang, Ho-Yeong Lim, Jong Youl Jin, Chang Yeol Yim, Hee Sook Park, Jun Suk Kim, Chang Hak Sohn, Soon Nam Lee; Cancer Res Treat. 2009;41(1):12-18. Published online March 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.1.12

Abstract PDF PubReader ePub

Purpose

Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer.

Materials and Methods

One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m²) or cisplatin (60 mg/m²) was given over 1 hour with 5-FU (1 gm/m²) on days 1~5 every 4 weeks.

Results

At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths.

Conclusion

Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.

Citations

Citations to this article as recorded by

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
Cancer Research and Treatment.2025; 57(1): 39. CrossRef
Quantum mechanical approaches and molecular docking analysis of platinum metal-based anticancer drugs Lobaplatin and Heptaplatin targeting cancer DNA - a comparative analysis
Madhavi Sahadevan, Mullainathan Sundaram, Karunagaran Subramanian
Chemical Physics Letters.2024; 842: 141191. CrossRef
Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
S. Shruthi, K. Bhasker Shenoy
ChemistrySelect.2024;[Epub] CrossRef
Recent Advances on Pt-Based Compounds for Theranostic Applications
Giulia Ferrari, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, Diego Montagner
Molecules.2024; 29(15): 3453. CrossRef
Hallmarks of anticancer and antimicrobial activities of corroles
Vinay K. Sharma, Yehuda G. Assaraf, Zeev Gross
Drug Resistance Updates.2023; : 100931. CrossRef
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
Dobrina Tsvetkova, Stefka Ivanova
Molecules.2022; 27(8): 2466. CrossRef
Second and third-row transition metal compounds containing benzimidazole ligands: An overview of their anticancer and antitumour activity
Galdina V. Suárez-Moreno, Delia Hernández-Romero, Óscar García-Barradas, Óscar Vázquez-Vera, Sharon Rosete-Luna, Carlos A. Cruz-Cruz, Aracely López-Monteon, Jesús Carrillo-Ahumada, David Morales-Morales, Raúl Colorado-Peralta
Coordination Chemistry Reviews.2022; 472: 214790. CrossRef
Metalofármacos en la terapia contra el cáncer
Elizabeth Márquez López, Esmeralda Sánchez Pavón, Rodolfo Peña Rodríguez, Delia Hernández Romero, José M. Rivera Villanueva, Raúl Colorado Peralta, David Morales Morales
TECNOCIENCIA Chihuahua.2022; 16(3): e1010. CrossRef
Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Dan Gibson
Journal of Inorganic Biochemistry.2021; 217: 111353. CrossRef
Monofunctional Platinum(II) Anticancer Agents
Suxing Jin, Yan Guo, Zijian Guo, Xiaoyong Wang
Pharmaceuticals.2021; 14(2): 133. CrossRef
Pt(IV) Prodrugs with NSAIDs as Axial Ligands
Daniil Spector, Olga Krasnovskaya, Kirill Pavlov, Alexander Erofeev, Peter Gorelkin, Elena Beloglazkina, Alexander Majouga
International Journal of Molecular Sciences.2021; 22(8): 3817. CrossRef
Multi-action Pt(IV) anticancer agents; do we understand how they work?
Dan Gibson
Journal of Inorganic Biochemistry.2019; 191: 77. CrossRef
TOXview: a novel graphical presentation of cancer treatment toxicity profiles
Lok Lam Ngai, Emil ter Veer, Héctor G. van den Boorn, E. Hugo van Herk, Jessy Joy van Kleef, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Acta Oncologica.2019; 58(8): 1138. CrossRef
Photoactivated platinum-based anticancer drugs
Muhammad Imran, Wagma Ayub, Ian S. Butler, Zia-ur-Rehman
Coordination Chemistry Reviews.2018; 376: 405. CrossRef
Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku
Cancer Chemotherapy and Pharmacology.2018; 81(6): 981. CrossRef
An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer
Dimitris Bertsimas, Allison O’Hair, Stephen Relyea, John Silberholz
Management Science.2016; 62(5): 1511. CrossRef
Platinum(iv) anticancer prodrugs – hypotheses and facts
Dan Gibson
Dalton Transactions.2016; 45(33): 12983. CrossRef
Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines
Pavel Štarha, Zdeněk Trávníček, Lucia Pazderová, Zdeněk Dvořák
Journal of Inorganic Biochemistry.2016; 162: 109. CrossRef
VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells
Sergey A. Shein, Ilya I. Kuznetsov, Tatiana O. Abakumova, Pavel S. Chelushkin, Pavel A. Melnikov, Anna A. Korchagina, Dmitry A. Bychkov, Irina F. Seregina, Mikhail A. Bolshov, Alexander V. Kabanov, Vladimir P. Chekhonin, Natalia V. Nukolova
Molecular Pharmaceutics.2016; 13(11): 3712. CrossRef
Condensations of single DNA molecules induced by heptaplatin and its chiral isomer
Hong-Yan Zhang, Yu-Ru Liu, Wei Li, Hui Li, Shuo-Xing Dou, Ping Xie, Wei-Chi Wang, Peng-Ye Wang
AIP Advances.2014;[Epub] CrossRef
Nanocarriers for delivery of platinum anticancer drugs
Hardeep S. Oberoi, Natalia V. Nukolova, Alexander V. Kabanov, Tatiana K. Bronich
Advanced Drug Delivery Reviews.2013; 65(13-14): 1667. CrossRef
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo
Investigational New Drugs.2012; 30(3): 1224. CrossRef
Cellular interactions of platinum drugs
Ezequiel Wexselblatt, Eylon Yavin, Dan Gibson
Inorganica Chimica Acta.2012; 393: 75. CrossRef
What do we know about the reduction of Pt(IV) pro-drugs?
Ezequiel Wexselblatt, Dan Gibson
Journal of Inorganic Biochemistry.2012; 117: 220. CrossRef
Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma
X.-L. Zhang, H.-J. Shi, S.-Z. Cui, Y.-Q. Tang, M.-C. Ba
European Journal of Surgical Oncology (EJSO).2011; 37(6): 466. CrossRef
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
Dalton Transactions.2010; 39(35): 8113. CrossRef

12,200 View
114 Download
26 Crossref

Gastrosplenic Fistula Complicated in a Patient with Non- Hodgkin's Lymphoma: Seong Eun Yang, Jong Youl Jin, Chi Won Song, Ji Chan Park, Jee In Lee, Wook Kim, Jeana Kim, Hae Giu Lee; Cancer Res Treat. 2002;34(2):153-156. Published online April 30, 2002; DOI: https://doi.org/10.4143/crt.2002.34.2.153

Abstract PDF

Reported cases of gastrosplenic fistulas are extremely rare in the literature. Malignancy is the primary cause in 50% of patients, followed by perforated peptic ulcer (40%). Fistulas can cause spleen rupture and potential bleeding that threaten the life of the patient. Lymphoma is the most common cause of malignancy complicated with gastrosplenic fistula. Most gastrosplenic fistulae caused by lymphoma eventually close following chemotherapy, although splenectomy should be performed to avoid further complications. We experienced a case of non-Hodgkin's lymphoma complicated with gastrosplenic fistula in a 21 year-old man. He was admitted to our hospital because of LUQ mass. On the abdominal CT, a splenic mass with central necrosis and gas was discovered. The biopsy specimen of the stomach and spleen displayed diffuse, large B cell type non-Hodgkin's lymphoma. After one cycle of CHOP chemotherapy, the LUQ mass was markedly regressed although the gastrosplenic fistula was still present on the follow-up CT. The fistula was treated by splenectomy and a partial resection of gastric fundus. Follow-up chemotherapy was continued after surgery.

Citations

Citations to this article as recorded by

SPONTANEOUS GASTROSPLENIC FISTULA: AN UNUSUAL PRESENTATION OF DIFFUSE LARGE B CELL LYMPHOMA
Hale Bülbül, Kader Irak, Selin Berk, Yusuf Ulusoy, Mesut Ayer
Gastroenterology Nursing.2022; 45(1): 63. CrossRef
Gastro-Splenic Fistula Related to Large B Cell Lymphoma
Diana Triantafyllopoulou, Ioannis Gkikas, Jagdish Adiyodi, Iain Crossingham, Shofiq Al-Islam, Muhammad Shahbaz Alam, Neil Sahasrabudhe, Ambareen Kausar, Ali Bin Ayub, Hazel Cowburn, Lisa Fox, Maqsood Punekar, Marian Macheta, Reuben Tooze
Reports.2020; 3(2): 17. CrossRef
Hand-assisted laparoscopic approach for the treatment of gastrosplenic fistula: A case report and review of the literature
Virginia Gallo, Luigi Pugliese, Francesco S. Latteri, Andrea Peri
Laparoscopic, Endoscopic and Robotic Surgery.2020; 3(4): 120. CrossRef
Successful Treatment of Gastrosplenic Fistula Arising from Diffuse Large B-Cell Lymphoma with Chemotherapy: Two Case Reports
Makoto Saito, Kencho Miyashita, Yosuke Miura, Shinpei Harada, Reiki Ogasawara, Koh Izumiyama, Akio Mori, Masanori Tanaka, Masanobu Morioka, Takeshi Kondo
Case Reports in Oncology.2019; 12(2): 376. CrossRef
Gastrosplenic fistula occurring in lymphoma patients: Systematic review with a new case of extranodal NK/T-cell lymphoma
Dong Hyeok Kang, Jimi Huh, Jong Hwa Lee, Yoong Ki Jeong, Hee Jeong Cha
World Journal of Gastroenterology.2017; 23(35): 6491. CrossRef
Lymphoma Causing Gastrosplenic Fistula Revealed by FDG PET/CT
Trent P. Wang, Mohan Doss, Jeffrey L. Tokar, Sanjay Reddy, Stefan K. Barta, Jian Q. Yu
Clinical Nuclear Medicine.2017; 42(11): 890. CrossRef
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib, Flavio G. Rocha, Dick G. Hwang, Brent T. Shoji
Journal of Clinical Oncology.2009; 27(20): e15. CrossRef

4,237 View
46 Download
7 Crossref

Acute Myeloid Leukemia with Trisomy 9 Following Chemotherapy of Non-Hodgkin's Lymphoma: Sung Won Jang, Dae Hoon Lee, Ju Yun Choi, Hong Gi Kim, Min Ho Choi, Sun Woo Kim, Jung Gon Suh, Jong Youl Jin, Dong Jip Kim; J Korean Cancer Assoc. 1997;29(3):512-515.

Abstract PDF: A 56-year-old male patient with non-Hodgkin's lymphoma achieved complete remission in July 1994 after receiving MACOP-B chemotherapy. 29 months after treatment, acute myeloid leukemia (AML, FAB subtypes M4) with trisomy 9 was developed. To our knowledge this is the first report of therapy-related AML with trisomy 9.

2,937 View
20 Download

Comparison of Tropisetron with Ondansetron in the Prevention of Cisplatin-induced Nausea and Vomiting: Kyung Shick Lee, Ji Youn Han, Hanlim Moon, Bok Kun Lee, Seok Goo Cho, Jong Youl Jin, Young Sun Hong, Hoon Kyo Kim; J Korean Cancer Assoc. 1997;29(2):332-339.

Abstract PDF: PURPOSE
Tropisetron (Nabovan (R)) is a new specific 5-HT3 receptor antagonist with a long terminal half life in plasma and high bioavailability after oral intake. We compared the antiemetic effectiveness and tolerability of tropisetron with ondansetron in the highly emetogenic chemotherapy (including cisplatin > or =50 mg/m2).
MATERIALS AND METHODS
Thirty-nine patients were administered in a randomized, multicenter, open, cross-over study and received either tropisetron plus dexamethasone (n=31) or ondansetron plus dexamethasone (n=34) during six days of two successive cycles of chemotherapy.
RESULTS
Total control of vomiting with either Ondansetron or tropisetron was 94.2 % vs 93.5 % in D1 (P=0.157); 90.6 % vs 93.1 % in D2 (P=0.18); 90.3 % vs 93.1 % in D3 (P=0.655); 96.4% vs 96.4 % in D4 (P=0.157); 96.4 % vs 100 % in D5 (P=0.317); 96.4 % vs 100% in D6, respectively. The duration of nausea showed significant decreasements in tropisetron at D5 and D6 (P=0.025, P=0.03, respectively), but the severity of nausea and performance status showed no significance. Headache and constipation were the most common side effects in both groups.
CONCLUSION
There was no significant difference in efficacy and tolerability between tropisetron and ondansetron in the cisplatin-based chemotherapy.

3,735 View
31 Download

A case of non-Hodgkin's lymphoma developed after radiotherapy in Hodgkin's disease: Young Boo Park, Jin Hyoung Kang, Jong Youl Jin, Hoon Kyo Kim, Kyung Shik Lee, Dong Jip Kim, Byung Kee Kim, Sun Moo Kim; J Korean Cancer Assoc. 1992;24(2):338-342.

Abstract PDF: No abstract available.

2,199 View
15 Download

Effects of ondansertron in the prevention of nausea and vomiting associated with chemotherapy in acute myelocytic leukemia: Woo Sung Min, Jong Youl Jin, Chi Wha Han, Chong Won Park, Chun Choo Kim, Dong Jip Kim; J Korean Cancer Assoc. 1992;24(2):288-292.

Abstract PDF: No abstract available.

2,577 View
15 Download

Alterating combination chemotherapy of cyclophosphamide, adriamycin, and vincristine(CAV) with etoposide and cisplatin(EP) in small cell lung cancer: Jong Wook Lee, Jin Hyoung Kang, Jong Youl Jin, Han Lim Moon, Young Seon Hong, Hoon Kyo Kim, Kyung Shik Lee, Dong Jip Kim, Sei Chul Yoon; J Korean Cancer Assoc. 1991;23(4):790-797.

Abstract PDF: No abstract available.

2,629 View
18 Download

Etoposide, adriamycin and cisplatin(EAP) chemotherapy in advanced gastric cancer: Jong Youl Jin, Kwang Moo Yoon, Hanlim Moon, Young Seon Hong, Hoon Kyo Kim, Kyung Shik Lee, Boo Sung Kim, Dong Jip Kim, Cho Hyun Park, In Chul Kim, Hyun Kwon Ha; J Korean Cancer Assoc. 1991;23(2):273-278.

Abstract PDF: No abstract available.

3,037 View
19 Download

A Case of Herpes Zoster Duplex in Patient with Malignant Lymphoma: Jong Youl Jin, Suk Joon Park, Seok Joong Yoon, Sung No Yun, Han Lim Moon, Hoon Kyo Kim, Moon Won Kang, Kyung Shik Lee, Dong Jip Kim; J Korean Cancer Assoc. 1990;22(2):352-355.

Abstract PDF: Herpes zoster occurs frequently in lymphoproliferative malignancy. In the majority, lesions confine to the skin in one or more adjacent dermatomes (localized zoster). But double dermatomes involve- ment (zoster duplex) occurs 0.15 to 0.5 percent of unselected patients with herpes zoster. A 59 years old female patient with malignant lymphoma showed multiple vesicles on right chest (T, dermatome area) and left arm (C, dermatome areal. The distribution of vesicles along nerve distribu- tion was characteristic pattern of herpes zoster. The patient was treated with topical application of calamin lotion, analgesics and acyclovir for 7 days. On the 7th hospital day, vesicle had changed to crust and discharged with improvement of pain.

3,193 View
18 Download

Treatment of Olfactory Neuroblastoma with Combination Chemotherapy and radiation Therapy: Jong Youl Jin, Choon Snag Bang, Hoon Kyo Kim, Kyung Shik Lee, Dong Jip Kim, Min Sik Kim, Seung Ho Cho, Byung Do Suh, Sei Chul Yoon, Kyu Ho Choi; J Korean Cancer Assoc. 1990;22(3):595-600.

Abstract PDF: Olfactory neuroblastoma (esthesioneuroblastoma) is very rare nasal tumor, which develops in the olfactory mucosa. Since the first description by Berger et al in 1924, about 200 cases have been reported in the literature. And there have been 3 reports since 1964 in Korea. All the reported cases in Korea were treated with surgical resection and or radiotherapy. The authors have experienced complete remission with combination chemotherapy and radiation therapy in a patient with olfactory neuroblastoma. A 55-year-old male presented with advanced unresectable olfactory neurobIastoma (stage C) and he was treated with combination chemotherapy (cisplatin, adriamycin, VM-26, cycloposphamide) every 3-4 weeks for 5 times followed by radition therapy (64BO cGy/36 fractions/9 weeks), which resulted in complete remission. The patient had been free of disease and asymptomatic for 8 months after treatment. Rescently left facial nerve palsy developed, of which etiology due to recurrence or treatment related fibrosis is unclear. Now, the authors are on study the etiology of left facial nerve palsy.

2,780 View
16 Download

High - dose Chemotherapy Followed by Autologous Bone Marrow Transplantation in High - risk Osteosarcoma and Ewing's Sarcoma: Ji Youn Han, Han Lim Moon, Dong Wook Kim, Jong Wook Lee, Jong Youl Jin, Chi Wha Han, Woo Sung Min, Chong Won Park, Choon Choo Kim, Dong Jip Kim, Hak Ki Kim, Young Gyun Woo, Jung Man Kim; J Korean Cancer Assoc. 1995;27(3):475-482.

Abstract PDF: Purpose
The poor histologic response to standard chemotherapy, a large tumor mass(more than 10 cm) at the time of the initial diagnosis, and tumors in axial bones are the risk factors for the relapse in sarcomas with preoperative and/or postoperative standard chemotherapy and curative surgery. Ta overcome these problems, high-dose chemotherapy and stem cell rescue with autologous bone marrow transplantation were done in four osteogenic and Ewings sarcomas. Methods: Bone-marrow harvest, cryopreservation and CFU-GM assay were done as described previously. As a high-dose chemotherapy, melphalan(160 mg/m) or ifosfamide(7,500 mg2/m)+etoposide(600mg/m) + carboplatin(600 mg/m(2)) were used. Bone marrow infusion and supportive cares were followed until the hematalogic recovery. Results: 1) The number of infused mononuclear cells and CFU-GM colonies were 0.8-2.9 x 10(8)/kg and 0.1-1.2 x 10(4)/kg, respectively. 2) The duration of absolute neutropenia(<500/mm(3)) and thrombocytopenia(<50,000/mm(3)) were 8-23 days and 0-25 days, respectively. 3) All but one had febrile neutropenia for 2 7 days due to sepsis and pneumonia. There waa no therapy associated death. 4) All patients had complete response and the duration of disease free survival was 5(+)-51(+) months. Of the four patients in complete response, one subsequently relapsed in scalp l0 months after transplantation and died 6 months later due to progression of disease. Conclasion: It seems that high-dose chemotherapy with atologous bone marrow transplantation is feasible in high-risk osteosarcoma and Ewing's sarcoma and the responsiveness to chemotherapy may be the most important factor to predict the prognosis.

2,808 View
17 Download

Effect of One - day ( G1 ) and Two - day ( G2 ) Schedule of Intravenous Granisetron on Prevention of nausea and Vomiting and Qualit Of Life during Cisplatin - Containin: Woo Sung Min, Han Lim Moon, Jin Hyoung Kang, Jong Youl Jin, Choon Choo Kim, Dong Jip Kim, Seong Ja Choo, Kyung Shim Kang, Jae Boon Ryu; J Korean Cancer Assoc. 1996;28(3):573-582.

Abstract PDF: Background
Nausea/vomiting is one of the most important item on deterioration of quality of life(QOL) in patients with cisplatin-containing chematherapy and may ultimately result in delay or refusal of the next chemotherapy. Although 5-hydroxy tryptamine 3(5-HT3) antagonist, ondansetron successfully controls cisplatin-induced nausea/vomiting during the first 24 hours, it fails to control nausea/vomiting on the following 24 hours in many patients. Authors performed this study to compare the effect of one-day and two-day schedule of intravenous granisetron on prevention of cisplatin-induced nausea and vomiting and QOL. Method: The antiemtic effect and QOL between one-day and two-day schedule of 3 mg/day of intravenous granisetron in cycle 1 and cycle 2 of cisplatin-based chemotherapy were compared. Frequency and severity of nausea/vomiting, QOL, oral intake and side effects were evaluated daily since day 0 to day 7 of chemotherapy. Results: Thirty eight patients were enrolled and 37 patients(31 male, 6 female, median age 60 with range of 42~74) were evaluable. The range of cisplatin were 50~l00mg/§³ and one or two of other chemotherapeutic agents such as 5FU, VP16, ifosfamide and mitomycin were combined. We evaluated the number of vomiting and QOL index with 10 items including nausea/vomiting and anorexia from day 0 to day 7 of chemotherapy. Twelve of 37 could not receive the G2 because of discontinuation of chemotherapy or patient's refusal of granisetron any more and eventually 25 had both Gl and G2. Time to first vomiting, control of vomiting and the amount of oral intake on day 1, day 2 and the worst day and side effects were not different between Gl and G2. QOL on day 2(G1; 56.2¡¾16.2 vs G2; 68.4¡¾20.3)(p<0.05) and change of QOL since day 1 to day 2 of cispltin(Gl; 16.3+2.1 vs G2 0.07+0.6)(p<0.01) were significantly different. Conclusion: Although the additiional intravenous granisetron on day 2 of cisplatin-based chemotherapy did not control nausea/vomiting more successfully, it improved QOL on the second day and the change of QOL from day 1 to day 2.

2,727 View
12 Download

Search